0000000000059888

AUTHOR

Philipp Harter

showing 11 related works from this author

Metastatic pattern of breast cancer according to immunohistochemical defined subtypes in the transitional phase of adjuvant trastuzumab treatment.

2014

e11581 Background: Prognosis of early breast cancer (BC) differs significantly upon subtypes (ST). Treatment with adjuvant trastuzumab improves outcome of HER2 overexpressing BC, however, less in k...

OncologyGynecologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentmedicine.diseaseTransitional phaseBreast cancerOncologyTrastuzumabInternal medicineMedicineImmunohistochemistryskin and connective tissue diseasesbusinessneoplasmsAdjuvantmedicine.drugEarly breast cancerJournal of Clinical Oncology
researchProduct

Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.

2010

Abstract Objective The excision repair cross-complementation group 1 (ERCC1) expression is a predictor of survival after surgical treatment for several malignancies. Its overexpression has been reported as a marker of platinum resistance in lung cancer. However, the relevance of ERCC1 expression in ovarian cancer (OC) is the subject of controversy, both as a predictive parameter for platinum resistance and because of its association with poor prognosis. Therefore, we performed a retrospective study investigating ERCC1 expression and its correlation with patients' survival in OC. Methods We analyzed the ERCC1 protein expression using four different ERCC1 antibodies (clone 8F1) with different…

OncologyAdultmedicine.medical_specialtyNeoplasm Residualmedicine.medical_treatmentERCC1 Protein ExpressionPredictive Value of TestsInternal medicineOvarian carcinomamedicineHumansLung cancerSurvival rateAgedNeoplasm StagingRetrospective StudiesAged 80 and overOvarian NeoplasmsChemotherapybusiness.industryAge FactorsObstetrics and GynecologyMiddle Agedmedicine.diseaseEndonucleasesImmunohistochemistryCystadenocarcinoma SerousDNA-Binding ProteinsSerous fluidOncologyFemaleERCC1businessOvarian cancerGynecologic oncology
researchProduct

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placeb…

2018

Summary Background Antiangiogenic therapy has known activity in ovarian cancer. The investigator-initiated randomised phase 2 TRIAS trial assessed the multi-kinase inhibitor sorafenib combined with topotecan and continued as maintenance therapy for platinum-resistant or platinum-refractory ovarian cancer. Methods We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 trial at 20 sites in Germany. Patients (≥18 years) with platinum-resistant ovarian cancer previously treated with two or fewer chemotherapy lines for recurrent disease were stratified (first vs later relapse) in block sizes of four and randomly assigned (1:1) using a web-generated response system to topotec…

0301 basic medicineSorafenibAdultmedicine.medical_specialtyTime FactorsPerforation (oil well)Angiogenesis InhibitorsPlatinum CompoundsNeutropeniaPlaceboGastroenterologyDrug Administration Schedule03 medical and health sciences0302 clinical medicineMaintenance therapyDouble-Blind MethodInternal medicineGermanyAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansProgression-free survivalProtein Kinase InhibitorsAgedOvarian Neoplasmsbusiness.industryMiddle AgedSorafenibmedicine.diseaseProgression-Free Survival030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisDisease ProgressionTopotecanFemaleTopoisomerase I InhibitorsbusinessTopotecanmedicine.drugThe Lancet. Oncology
researchProduct

Synchronous Ovarian and Endometrial Cancer—an International Multicenter Case-Control Study

2013

ObjectivesThis study aimed to compare the prognosis of patients with synchronous endometrial and ovarian cancer (SEOC) to matched controls with either endometrial cancer (EC) or ovarian cancer (OC).MethodsA retrospective case-control study including all patients with SEOC who had been treated at 5 European tertiary gynecologic oncology centers between 1996 and 2011 and patients with either EC or OC matched for age, International Federation of Gynecology and Obstetrics (FIGO) stage, histology, year of diagnosis, and Eastern Cooperative Oncology Group performance score.ResultsThe study cohort comprised 77, 132, and 126 patients with SEOC, EC, and OC, respectively. The patient characteristics …

medicine.medical_specialtyMedizinGynecologic oncologyDisease-Free SurvivalCohort StudiesNeoplasms Multiple PrimaryTertiary Care CentersGermanymedicineHumansStage (cooking)Retrospective StudiesOvarian NeoplasmsGynecologybusiness.industryEndometrial cancerCarcinomaCase-control studyObstetrics and GynecologyRetrospective cohort studyMiddle Agedmedicine.diseaseEndometrial NeoplasmsOncologyCase-Control StudiesCohortFemalebusinessOvarian cancerCohort studyInternational Journal of Gynecologic Cancer
researchProduct

Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.

2009

BACKGROUND: Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is a relatively new disease. The aim of this study was to evaluate the prevalence of BP-ONJ in breast cancer patients with osseous metastasis and bisphosphonate therapy. METHODS: A retrospective study was conducted in a EUSOMA accredited breast unit in Germany. All patients treated from January of 2000 to March of 2006 with metastatic breast cancer and bisphosphonate therapy were reviewed. All patients were contacted, and missing data were completed through structured interviews with their dentists and physicians (n = 75). Primary outcome was the development of BP-ONJ and the detection of possible additional trigger fa…

AdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentOral Surgical ProceduresBone NeoplasmsBreast NeoplasmsBreast cancerInternal medicineMedicineHumansAgedRetrospective StudiesAged 80 and overBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)IncidenceOsteonecrosisBone metastasisCancerRetrospective cohort studyBisphosphonateMiddle Agedmedicine.diseasePrognosisMetastatic breast cancerSurgeryOncologyBreast diseasebusinessJaw DiseasesCancer
researchProduct

Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?

2020

Objective: The therapeutic role of pelvic and para-aortic lymphadenectomy in surgical staging of apparent early-stage epithelial ovarian cancer (eEOC) is still under debate. The aim of this study was to evaluate the potential therapeutic role of systematic lymphadenectomy in patients with eEOC. Methods: Multi-center retrospective cohort study, comparing women with apparent eEOC who underwent comprehensive bilateral pelvic and para-aortic lymphadenectomy (defined as ≥20 lymph nodes) versus patients receiving no lymphadenectomy or lymph node sampling, from 05/1985 to 12/2016. Patients with bulky nodes at CT-scan and those without complete intra-peritoneal surgical staging were excluded. Only …

0301 basic medicinemedicine.medical_specialtyPrognosimedicine.medical_treatmentEarly-stageLymph node samplingCarcinoma Ovarian EpithelialDisease-Free SurvivalPelvisLymph node samplingCohort StudiesSurgical staging03 medical and health sciences0302 clinical medicineOvarian cancerMedicineHumansEpithelial ovarian cancerStage (cooking)early-stage; lymph node sampling; lymphadenectomy; ovarian cancer; prognosis; surgical stagingNeoplasm StagingRetrospective StudiesOvarian NeoplasmsChemotherapybusiness.industryObstetrics and GynecologyRetrospective cohort studyLymphadenectomyMiddle Agedmedicine.diseaseSurvival RateSettore MED/40 - GINECOLOGIA E OSTETRICIA030104 developmental biologyOncology030220 oncology & carcinogenesisLymphatic MetastasisLymph Node ExcisionLymphadenectomyFemaleLymphRadiologyLymph NodesprognosisbusinessOvarian cancer
researchProduct

Topotecan (T) ± sorafenib (S) in platinum-resistant ovarian cancer (PROC): A double-blind placebo-controlled randomized NOGGO–AGO intergroup Trial—TR…

2016

5522Background: Sorafenib (S), a multi TK-inhibitor in combination with topotecan (T), a topoisomerase inhibitor showed preclinical synergistic effects in ovarian cancer but critical toxicity. To a...

SorafenibOncologyCancer Researchmedicine.medical_specialty030219 obstetrics & reproductive medicineendocrine system diseasesmedicine.drug_classbusiness.industryPlacebomedicine.diseasefemale genital diseases and pregnancy complicationsDouble blind03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineToxicitymedicineTopotecanbusinessOvarian cancerTopoisomerase inhibitormedicine.drugPlatinum resistantJournal of Clinical Oncology
researchProduct

Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study

2020

ObjectiveObesity is associated with worse survival and an increased risk of relapse in several malignancies. The influence of obesity on vulvar cancer recurrence has not been previously described. The primary objective of this study was to evaluate the association between obesity and tumor recurrence in patients with vulvar cancer.MethodsThis is an analysis of the AGO-CaRE-1 study. Patients diagnosed with squamous cell vulvar cancer (stage IB and higher), treated in 29 cancer centers between January 1998 and December 2008, were registered in a centralized database. The cohort was divided into two gropus depending on the body mass index (BMI) (<30 vs ≥30 kg/m²). Descriptive statistics, su…

Adultmedicine.medical_specialtyBody Mass IndexYoung Adult03 medical and health sciences0302 clinical medicineQuality of lifeGermanyInternal medicinemedicineHumansObesityAgedNeoplasm StagingAged 80 and over030219 obstetrics & reproductive medicineVulvar Neoplasmsbusiness.industryObstetrics and GynecologyCancerMiddle AgedVulvar cancermedicine.diseaseObesityIncreased riskOncologyTime to recurrence030220 oncology & carcinogenesisCohortCarcinoma Squamous CellFemaleNeoplasm Recurrence LocalbusinessBody mass indexInternational Journal of Gynecologic Cancer
researchProduct

LION-PAW: Lymphadenectomy in ovarian neoplasm-pleasure ability of women—Prospective substudy of the randomized multicenter LION study.

2018

5575Background: There is limited information regarding the impact of radical surgery including pelvic and para-aortic lymphadenectomy (LNE) and subsequent chemotherapy on sexuality in patients (pts...

Cancer ResearchChemotherapymedicine.medical_specialty030219 obstetrics & reproductive medicinebusiness.industrymedicine.medical_treatmentmedia_common.quotation_subjectGeneral surgerymedicine.diseasePleasure03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesismedicineNeoplasmLymphadenectomyIn patientRadical surgerybusinessmedia_commonJournal of Clinical Oncology
researchProduct

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

2013

Journal article TERT-locus SNPs and leukocyte telomere measures are reportedly associated with risks of multiple cancers. Using the Illumina custom genotyping array iCOGs, we analyzed ~480 SNPs at the TERT locus in breast (n = 103,991), ovarian (n = 39,774) and BRCA1 mutation carrier (n = 11,705) cancer cases and controls. Leukocyte telomere measurements were also available for 53,724 participants. Most associations cluster into three independent peaks. The minor allele at the peak 1 SNP rs2736108 associates with longer telomeres (P = 5.8 × 10!-7), lower risks for estrogen receptor (ER)-negative (P = 1.0 × 10!-8) and BRCA1 mutation carrier (P = 1.1 × 10!-5) breast cancers and altered promot…

TelomeraseMessengerCàncer d'ovariEstrogen receptorAetiology screening and detection [ONCOL 5]0302 clinical medicineBreast cancerRisk FactorsAlternative Splicing; Biomarkers Tumor; Breast Neoplasms; Case-Control Studies; Chromatin; DNA Methylation; Female; Gene Expression Profiling; Genetic Loci; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Luciferases; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Polymorphism Single Nucleotide; RNA Messenger; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Telomerase; Telomere; GeneticsGenotypeBUCCAL CELLSLuciferasesTelomeraseOligonucleotide Array Sequence AnalysisOvarian Neoplasms0303 health sciencesTumorTelòmerReverse Transcriptase Polymerase Chain ReactionGENETIC-VARIATIONCOMMON VARIANTSSingle Nucleotidetert-clptm1l locus; genome-wide association; genetic-variation; susceptibility loci; buccal cells; fibroblasts; common variants; carcinoma; reverse-transcriptase htert; metaanalysisTelomereAetiology screening and detection Immune Regulation [ONCOL 5]Chromatin3. Good healthTumor Markers Biological030220 oncology & carcinogenesisFemaleFIBROBLASTSGenotypeSUSCEPTIBILITY LOCICARCINOMASingle-nucleotide polymorphismBreast NeoplasmsBiologyReal-Time Polymerase Chain ReactionPolymorphism Single NucleotideArticleCàncer de mama03 medical and health sciencesBreast cancerSDG 3 - Good Health and Well-beingTranslational research [ONCOL 3]Ovarian cancermedicineGeneticsBiomarkers TumorHumansGenetic Predisposition to DiseaseRNA MessengerPolymorphismAlleleGENOME-WIDE ASSOCIATIONMETAANALYSIS030304 developmental biologyMolecular epidemiology Aetiology screening and detection [NCEBP 1]Breast cancer susceptibilityHereditary cancer and cancer-related syndromes [ONCOL 1]Translational research Genomic disorders and inherited multi-system disorders [ONCOL 3]Gene Expression ProfilingDNA Methylationmedicine.diseaseMolecular biologyTERT-CLPTM1L LOCUSTelomereMinor allele frequencyAlternative SplicingGenetic LociCase-Control StudiesRNABiomarkersREVERSE-TRANSCRIPTASE HTERTGenome-Wide Association StudyNature genetics
researchProduct

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.

2019

Lymph node ratio (LNR) can predict treatment outcome and prognosis in patients with solid tumors. Aim of the present analysis was to confirm the concept of using LNR for assessing outcome in patients with vulvar cancer after surgery with inguinal lymphadenectomy in a large multicenter project.The AGO-CaRE-1 study multicenter database was used for analysis. LNR was defined as ratio of number of positive lymph nodes (LN) to the number of resected. Previously established LNR risk groups were used to stratify patients. LNR was investigated with respect to clinical parameters. Univariate and multivariable survival analyses were performed to assess the value of LNR in order to predict overall (OS…

0301 basic medicineOncologyMalemedicine.medical_specialtyMedizinInguinal lymphadenectomyRisk AssessmentVulva03 medical and health sciences0302 clinical medicineRisk groupsPredictive Value of TestsInternal medicineNodal statusGermanymedicineHumansIn patientLymph nodeAgedNeoplasm StagingRetrospective StudiesVulvar Neoplasmsbusiness.industryObstetrics and GynecologyVulvar cancerMiddle Agedmedicine.diseasePrognosisSurvival Analysis030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous CellLymph Node ExcisionFemaleLymphLymph NodesbusinessGynecologic oncology
researchProduct